IPO UPDATE: Intrexon rises 81% in 2 days; also Sophiris, Ruthigen, Acceleron, Iroko

Intrexon chairman and CEO Randal Kirk took a page from Quintiles executive chairman Dennis Gillings's playbook and cashed in on his investments in the synthetic biology company with an initial public offering that increased the majority shareholder's net worth by another $1 billion.